Stronger intervention by the government in controlling price, accessibility, and availability of MS treatment can drive innovation, said Aliza Ben-Zacharia, DNP, ANP, associate director at the Center for Nursing Research and Innovation at Mount Sinai.
Stronger intervention by the government in controlling price, accessibility, and availability of MS treatment can drive innovation, said Aliza Ben-Zacharia, DNP, ANP, associate director at the Center for Nursing Research and Innovation at Mount Sinai.
Transcript
Are there any policies that you would like to see enacted that would help improve affordability of MS treatment for the patients you serve?
Absolutely, I think 1 of the policies is the government has to control the price of the medication. That's what you have in European countries and in other countries that you can really develop these new policies and really control the price of the medications. I don't think that pharmaceuticals will provide it for free, and that's not my goal, but I don't think that you can allow anything to be so expensive—the thousands and thousands of dollars of the price of medication, and in some other diseases more than $100,000. I think nobody can really afford these medications, and because of it, some of the insurance policies become more expensive. The main policy is that everyone in the United States with MS should have access to medication and should be treated for their lifetime on medication. If clinician decides that the patient needs a different medication, not the insurance 1; 2, that's another policy that's very painful for me–I will prescribe a medication and then the insurance will give me their whole spiel about tier 1, level 1, level 2, no patient has to be on this, then on this–who gave them the right to make decisions about what medication patients will go on?
They don't have the knowledge, they don't have the expertise, they don't look at the MRI of patients, they don't look at the clinical presentation of patients; but yet, they make a decision about what medication. I think a policy has to be done and developed about these insurance companies. It's so important, and really patients need access to these medications. Either they have a relapsing course or progressive course—children, adult, elderly–everyone should be entitled and given this medication to control their disease. So, I think those 2 policies about access and affordable, but really controlling the price of the medication is number 1. Number 2, making sure that it's available to all patients and really controlling insurance company a bit. Just really, I think the government needs to get involved with insurance companies. They have in the past with pre-existing conditions, which was excellent so everyone can get it; but nowadays, they really have to intervene and create the policy for insurance to not intervene with care of patient–they should not make that decision.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More